Enterobacteriaceae that are resistant to carbapenem antimicrobials through the production of carbapenemase are known as carbapenamase-producing Enterobacteriaceae (CPE). Because CPE are resistant to many antibiotics that are considered the last line of defense, treatment of infections with CPE may be difficult.
It is important to screen individuals at risk of acquiring CPE so that appropriate infection prevention and control (IPAC) measures can be implemented promptly for those who test positive for CPE. These IPAC measures include hand hygiene, providing care with recommended personal protective equipment in a single room, routine cleaning and disinfection of shared medical equipment, and effective environmental cleaning according to best practices. If you have questions about IPAC resources for CPE please visit Carbapenemase-producing Enterobacteriaceae (CPE) or contact email@example.com.
Announcement: CPE voluntary surveillance program discontinued
Please note that the CPE voluntary surveillance program that was established by PHO in collaboration with the Ministry of Health and Long‐Term Care (MOHLTC) in 2011 has been discontinued, as CPE is now reportable. The MOHLTC updated the Health Protection and Promotion Act (HPPA) and its regulations for reporting Diseases Of Public Health Significance (DOPHS), formerly known as the ‘Ontario Reportable Disease List’, to include CPE colonization and infection, effective Tuesday, May 1, 2018.
For guidance on reporting CPE, please see the Infectious Diseases Protocol, 2018 (Appendix A - Disease Specific Chapter and Appendix B - Case Definition), or contact your local public health unit.